Aerin Medical, Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Aerin Medical, Inc. - overview

Established

2011

Location

Austin, TX, US

Primary Industry

Medical Devices & Equipment

About

Aerin Medical, Inc. is a US-based company specializing in innovative treatment solutions for nasal conditions. They focus on providing non-invasive procedures to alleviate symptoms related to Nasal Airway Obstruction and chronic rhinitis. Founded in 2011 and headquartered in Austin, Texas, Aerin Medical develops proprietary technologies for nasal treatments.


The company has successfully raised USD 32. 48 mn in Series G funding as of December 13, 2024, which will support its operations and development efforts. The CEO, Matt Brokaw, leads the company, which has completed 9 deals to date. Aerin Medical specializes in innovative treatment solutions for nasal conditions, particularly focusing on Nasal Airway Obstruction (NAO) and chronic rhinitis.


Their core products include VivAer® and RhinAer®, non-invasive options utilizing temperature-controlled radiofrequency technology designed to provide long-lasting relief from congestion, breathing difficulties, and chronic rhinitis symptoms. These procedures are conducted in medical settings, making them convenient for patients and seamlessly integrating into existing clinical practices. The primary customer base comprises healthcare providers across the United States. Aerin Medical generates revenue by providing specialized medical procedures directly to healthcare providers through B2B transactions.


Physicians and clinics perform treatments using Aerin Medical's proprietary technology and may enter into partnerships with healthcare facilities offering VivAer® and RhinAer® treatments. The firm's revenue model revolves around procedure-based pricing, allowing healthcare providers to charge patients directly for the treatments, supported by the clinical benefits of its technology. In December 2024, Aerin Medical, Inc. raised USD 32.


48 mn in Series G funding, co-led by KCK MedTech, Questa Capital, OrbiMed, and Ally Bridge Group, with new participation from Ares Capital. The company plans to utilize this funding to enhance its operations and further develop its product offerings. While specific new products are not detailed, the company is likely focused on expanding its reach within the current market and potential new geographic regions.


Current Investors

Targeted Technology, KCK Group, Horizon Technology Finance Corporation

Primary Industry

Medical Devices & Equipment

Sub Industries

Therapeutic Devices

Website

www.aerinmedical.com/

Verticals

HealthTech, Manufacturing

Company Stage

Series G

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.